Levenstein J H
S Afr Med J. 1981 Jun 13;59(25):893-9.
In part I of this article we report on 89 hypertensive patients who underwent 9 months of treatment with oxprenolol HCl 160 mg in a slow-release formulation plus cyclopenthiazide 0.25 mg and potassium chloride 600 mg (Trasidrex; Ciba-Geigy). Blood pressures, both supine and standing, and pulse rates were consistently controlled by this regimen throughout the 9 months of treatment, regardless of the time of day at which these parameters were measured, i.e. morning or afternoon. Seventy-six patients completed the trial. The most common symptom or sign occurring during treatment was headache, the next most common being heartburn. No patient developed angina while on the regimen. Three patients discontinued the study owing to unwanted effects. This study represents a total of 28237 patient-days of treatment. In part II of the trial we studied the effects of a similar regiment in 67 patients for 1 year preceded by a 2-week wash-out period. Forty-six of the patients completed a full year's treatment. Statistically significant reductions in blood pressures and pulse rates occurred after commencement of active treatment and were maintained throughout the study period. Four patients withdrew from the study owing to adverse effects, 1 patient died of an acute myocardial infarction, and 1 patient was considered a treatment failure. This study represents 19858 patient-days of treatment.
在本文的第一部分，我们报告了89例高血压患者，他们接受了为期9个月的治疗，使用的药物为盐酸氧烯洛尔160毫克缓释制剂加环戊噻嗪0.25毫克和氯化钾600毫克（Trasidrex；汽巴 - 嘉基公司）。在整个9个月的治疗期间，无论测量这些参数的时间是上午还是下午，仰卧位和站立位的血压以及脉搏率均通过该治疗方案得到持续控制。76例患者完成了试验。治疗期间出现的最常见症状或体征是头痛，其次是烧心。在该治疗方案下，没有患者发生心绞痛。3例患者因不良反应而退出研究。该研究总计有28237个患者治疗日。在试验的第二部分，我们在67例患者中研究了类似治疗方案的效果，治疗期为1年，之前有2周的洗脱期。46例患者完成了全年的治疗。积极治疗开始后，血压和脉搏率出现了具有统计学意义的下降，并在整个研究期间得以维持。4例患者因不良反应退出研究，1例患者死于急性心肌梗死，1例患者被视为治疗失败。该研究有19858个患者治疗日。
